[Clinical study on the treatment of dyskinesia by L-stepholidine].
134 cases of dyskinesia caused by various CNS diseases were treated with a new type of DA blocker L-Stepholidine (1-SPD). Good response was obtained in 72% (29/40) of L-dopa induced abnormal involuntary movements in Parkinson disease, 79% (34/43) of Tourette syndrome, and 65% (15/23) of tardive dyskinesia through a short-term follow-up. No serious side effects were found within the therapeutic dosage of 50-225mg/day The results showed that L-SPD is a new type of anti-dyskinesia agent deserving further pharmacological investigation.
Le
W
W
D000368:Aged; D001599:Berberine / Q000031:analogs & derivatives / Q000627:therapeutic use*; D001600:Berberine Alkaloids / Q000627:therapeutic use*; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy*; D015337:Multicenter Studies as Topic; D005879:Tourette Syndrome / Q000188:drug therapy
D001600:Berberine Alkaloids; D001599:Berberine; C010513:stepholidine; D007980:Levodopa